Clinical trial
A Phase I Study of Intratumoral Injections of CpG-STAT3 siRNA (CAS3/SS3) in Combination With Local Radiation in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL)
NCT04995536 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Intratumoral Injections of CpG-STAT3 siRNA (CAS3/SS3) in Combination With Local Radiation in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL)
- Lead sponsor
- City of Hope Medical Center
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- July 27, 2021
- Completion date
- January 4, 2024
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent b-cell non-hodgkin lymphoma, recurrent diffuse large b-cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent grade 3a follicular lymphoma, recurrent grade 3b follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, refractory b-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory grade 1 follicular lymphoma, refractory grade 2 follicular lymphoma, refractory grade 3 follicular lymphoma, refractory grade 3a follicular lymphoma, refractory grade 3b follicular lymphoma, refractory mantle cell lymphoma, refractory marginal zone lymphoma, refractory small lymphocytic lymphoma